Company intelligence / Profile preview

Immunoclin

London, United Kingdom

Ownership: Private
Development stage: Other

Overview

Immunoclin is focused on developing personalized medicine platforms, prognostic tests, novel anti-infectious and anti-inflammatory therapies, and nutritional formulations, but no advanced clinical results are publicly disclosed. The company's core stage appears to be early/pre-clinical research, with a portfolio heavily focused on diagnostics, analytical and non-destructive testing, and early-stage biotech innovations.

Therapeutic areas: Infectious DiseasesGastroenterologyCardiovascularOncologyNeurology
Modalities: Small moleculeNutraceuticalBiologicDiagnostic
Industry: Biotech

Beyond the preview

Go deeper on Immunoclin.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunoclin.

Explore the full profile